Skip to content
value.today

Radient Pharmaceuticals Corp

Total raised
$19 M
2 rounds on record
Latest round
$8 M
Jan 2011
First round on record
Mar 2010
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Radient Pharmaceuticals Corp
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2011$8 MNo. 2$2 to $10 million

Radient Pharmaceuticals Corp: Raise no. 2, Jan 2011

Investors in this round

5 investors had bought by the notice of Feb 14, 2011: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
$890
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$500,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Akio Ariura · Executive Officer · CFO
  • Douglas MacLellan · Director, Executive Officer
  • Michael Boswell · Director
  • Minghui Jia · Director
  • Robert Beart · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Financial West Group (CRD 2807598) · Westlake Village, CaliforniaSold in CA, NY

Remarks in the notice

  • On fees: “Financial West Group also received 5 year warrants to purchase up to 839,552 shares of the issuer's Common Stock at an exercise price of $0.67 per share.”

Signed by Akio Ariura, Cfo. Source: SEC Form D, newest notice filed Feb 14, 2011. Read the notice at the SEC.

debt, optionsSEC
Mar 2010$11 MNo. 1$10 to $50 million

Radient Pharmaceuticals Corp: Raise no. 1, Mar 2010

Investors in this round

36 investors had bought by the notice of Apr 30, 2010: 36 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$11 M of $11 M offered
Smallest investment taken
$2,500
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$5 million to $25 million
Sales commissions
none
Finders' fees
$839,000
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks finders' fees as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Akio C. Ariura · Executive Officer, Director
  • Douglas C. MacLellan · Executive Officer, Director
  • Minghui (Henry) r Jia · Director
  • edward r arquilla · Director
  • michael r boswell · Director
  • william m. thompson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On fees: “Includes finders' fees, costs and expense of offering”
  • On the amounts: “Represents aggregate principal amount of 12% convertible notes isued in offering, exclusive of warrants for which no additional consideration was received.”
  • On the use of proceeds: “excludes accured payroll”

Signed by rachael schmierer, counsel. Source: SEC Form D, newest notice filed Apr 30, 2010. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Radient Pharmaceuticals Corp had no revenue when it filed its newest notice of a funding round (Feb 2011).

    SEC Form D (revenue range) · Feb 2011

  • Revenue range over time, as stated in its notices: revenue between $5 million and $25 million in 2010; no revenue in 2011.

    SEC Form D (revenue range) · Feb 2011

  • The industry group it chose in its notices: Other.

    SEC Form D · Feb 2011

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Radient Pharmaceuticals Corp is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 36 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Radient Pharmaceuticals Corp
NameRoleNamed in
Akio AriuraCFOFeb 2011
Douglas MacLellanExecutive officerFeb 2011
Akio C. AriuraExecutive officerApr 2010
Douglas C. MacLellanExecutive officerApr 2010
Douglas MacLellanDirectorFeb 2011
Michael BoswellDirectorFeb 2011
Minghui JiaDirectorFeb 2011
Robert BeartDirectorFeb 2011
Akio C. AriuraDirectorApr 2010
Douglas C. MacLellanDirectorApr 2010
Minghui (Henry) r JiaDirectorApr 2010
edward r arquillaDirectorApr 2010
michael r boswellDirectorApr 2010
william m. thompsonDirectorApr 2010